190 related articles for article (PubMed ID: 3316519)
1. High-dose methotrexate: a critical reappraisal.
Ackland SP; Schilsky RL
J Clin Oncol; 1987 Dec; 5(12):2017-31. PubMed ID: 3316519
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
4. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
5. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
6. Concepts in use of high-dose methotrexate therapy.
Treon SP; Chabner BA
Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
8. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
Camitta BM; Holcenberg JS
Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Diddens H; Teufel T; Niethammer D
Cancer Chemother Pharmacol; 1987; 20(2):128-32. PubMed ID: 3499251
[TBL] [Abstract][Full Text] [Related]
10. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
Frei E; Blum RH; Pitman SW; Kirkwood JM; Henderson IC; Skarin AT; Mayer RJ; Bast RC; Garnick MB; Parker LM; Canellos GP
Am J Med; 1980 Mar; 68(3):370-6. PubMed ID: 6965819
[TBL] [Abstract][Full Text] [Related]
11. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
12. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
13. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP; Goodyear MD; Levine MN; Russell R; Archibald SD; Young JE
J Clin Oncol; 1990 Feb; 8(2):203-8. PubMed ID: 2405105
[TBL] [Abstract][Full Text] [Related]
15. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
Beh SC; Kildebeck E; Narayan R; Desena A; Schell D; Rowe ES; Rowe V; Burns D; Whitworth L; Frohman TC; Greenberg B; Frohman EM
J Neurol Sci; 2017 Jan; 372():187-195. PubMed ID: 28017209
[TBL] [Abstract][Full Text] [Related]
17. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
18. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Cohen IJ
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1057-1065. PubMed ID: 28455583
[TBL] [Abstract][Full Text] [Related]
19. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
Dhingra H; Kalra M; Mahajan A
Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
